AlgavitaBio, Inc.
AlgavitaBio, Inc.
  • Home
  • About
  • Contact
  • More
    • Home
    • About
    • Contact

  • Home
  • About
  • Contact

Development

Image of a sodium channel blocker

Neosaxitoxin (NeoSTX) is a Site-1 sodium channel blocker that differs from existing local anesthetics

  • Avoids local and systemic toxicities of existing agents
  • profound synergy and prolonged duration when combined with existing local anesthetics and epinephrine
  • No delivery system required
  • Easily injectable, small gauge needles

Graph showing the time course of the nerve block

Combination of NeoSTX, bupivacaine and epinephrine duplicates earlier work showing increased duration of analgesia vs Site-1 blocker alone

  • NeoSTX-bupivacaine-epinephrine analgesic duration 6-fold longer than bupivacaine alone
  • Rat sciatic nerve block

Graph showing prolonged analgesia duration with a higher dose of NeoSTX

Neo3 has the potential to provide effective regional anesthesia and prolonged analgesia

Neo3 is a phase 2-ready injectable combining: 

  • NeoSTX– a novel site-1 sodium channel blocker with ultra-long duration of effect
  • Bupivacaine & Epinephrine – which act synergistically with NeoSTX to enhance efficacy, prolong duration, and improve safety by limiting systemic exposure

Efficacy:

  •  Neo3 provides rapid, dense surgical anesthesia and prolonged post-surgical analgesia 

 Safety:

 

  • No serious adverse events (SAEs), excellent safety profile to date
  • NeoSTX has no direct cardiotoxicity. 
  • Systemic effects on respiratory and skeletal muscle strength are minimal at anticipated clinical doses
  • Site-1 sodium channel blockers are largely devoid of toxicity to muscles and nerves and produce no local inflammation

Copyright © 2025 AlgavitaBio, Inc.  - All Rights Reserved.

  • Home

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept